ArticleScientific reports2018
Increased levels of circulating MMP3 correlate with severe rejection in face transplantation.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Machine learning identification of biomarkers for vascular endothelial damage in obstructive sleep apnea.Clinics (Sao Paulo, Brazil) · 2026Article
- Chronic Rejection in Facial Vascularized Composite Allotransplantation (fVCA).Results and problems in cell differentiation · 2026Review
- Immunosuppressive and antiinfectious regimens in vascular composite allograft recipients-a systematic review.Frontiers in transplantation · 2025Review
- Addressing statistical challenges in the analysis of proteomics data with extremely small sample size: a simulation study.BMC genomics · 2024Article
- Immunogenicity and tolerance induction in vascularized composite allotransplantation.Frontiers in transplantation · 2024Review
- Methods of ex vivo analysis of tissue status in vascularized composite allografts.Journal of translational medicine · 2023Review
- T cell-attracting CCL18 chemokine is a dominant rejection signal during limb transplantation.Cell reports. Medicine · 2022Article
- Clinical and preclinical tolerance protocols for vascularized composite allograft transplantation.Archives of plastic surgery · 2021Article
- Recognizing Emotional Expression as an Outcome Measure After Face Transplant.JAMA network open · 2020Article
- Blood proteome profiling using aptamer-based technology for rejection biomarker discovery in transplantation.Scientific data · 2019Article
- Neutrophil activation in systemic capillary leak syndrome (Clarkson disease).Journal of cellular and molecular medicine · 2019Article
- Noninvasive Monitoring of Allograft Rejection Using a Novel Epidermal Sampling Technique.Plastic and reconstructive surgery. Global open · 2019Article
- The Evolving Clinical Presentation of Acute Rejection in Facial Transplantation.JAMA facial plastic surgery · 2019Article
- MMP3 Is a Non-invasive Biomarker of Rejection in Skin-Bearing Vascularized Composite Allotransplantation: A Multicenter Validation Study.Frontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Face transplantation is a viable treatment option for carefully selected patients with devastating injuries to the face. However, acute rejection episodes occur in more than 80% of recipients in the first postoperative year. Unfortunately, neither a correlation between histological grades of rejection and anti-rejection treatment nor systemic surrogate markers of rejection in face transplantation are established in clinical routine. Therefore, we utilized next generation aptamer-based SOMAscan proteomics platform for non-invasive rejection biomarker discovery. Longitudinal serum samples from face transplant recipients with long-term follow-up were included in this study. From the 1,310 proteins analyzed by SOMAscan, a 5-protein signature (MMP3, ACY1, IL1R2, SERPINA4, CPB2) was able to discriminate severe rejection from both no-rejection and nonsevere rejection samples. Technical validation on ELISA platform showed high correlation with the SOMAscan data for the MMP3 protein (r
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.